iSpecimen Inc. (ISPC) 股票分析

公司概述

iSpecimen Inc. operates a specialized marketplace that facilitates the provision of biospecimens to life science researchers globally. The company develops and maintains the iSpecimen Marketplace, a proprietary online platform designed to connect medical researchers requiring access to subjects, samples, and data with hospitals and laboratories. This entity functions within the Healthcare sector, specifically under the Diagnostics & Research industry, positioning it as an intermediary in the biomedical supply chain. The company currently holds a market capitalization of $3.86 million, generates annual revenue of $1.93 million, and employs 7 individuals. These valuation and revenue figures indicate that the company operates on a very small scale with limited market penetration, reflecting the early-stage nature of its business model where operational costs and infrastructure development often outweigh immediate revenue generation in the diagnostic and research space.

财务健康

The company reports trailing twelve-month revenue of $1.93 million, yet it records a significant net loss of $10,487,532 and an EBITDA of $-8,717,890. The substantial negative gap between the modest revenue of $1.93 million and the net loss exceeding ten million dollars reveals a highly aggressive cost structure characterized by operating expenses that far exceed current earnings power. Free cash flow stands at $-2,782,585, which indicates that the company is burning cash rather than generating liquidity, thereby limiting its financial flexibility to fund operations without external capital raises. The gross margin is extremely low at 1.2%, while the operating margin is deeply negative at -5192.9% and the profit margin is effectively 0.0%, suggesting that cost of goods sold and operating expenditures are disproportionately high relative to sales volume. On the balance sheet, the company holds $6.88 million in cash against $268,798 in debt, resulting in a debt-to-equity ratio of 8.70 which technically indicates a leveraged position, although the high cash balance mitigates immediate solvency risks. The current ratio is 1.12, indicating that the company possesses just enough current assets to cover its current liabilities, reflecting a tight but manageable short-term liquidity position. Furthermore, the return on equity is -327.8% and the return on assets is -59.4%, metrics that reveal that management has not yet achieved positive returns on the capital invested in the business, highlighting the challenges inherent in scaling a loss-making biotechnology or diagnostic infrastructure play.

估值评估

The trailing P/E ratio is not applicable (N/A) due to negative earnings, while the forward P/E is calculated at -0.16, implying that the market prices the stock based on future expectations rather than historical profitability. The price-to-book ratio is 0.41, indicating that the market values the company at less than half of its net asset book value, which typically suggests the market views the company's assets or future prospects as undervalued or potentially distressed. The price-to-sales ratio is 2.00, and the EV/EBITDA stands at 0.32; these alternative valuation metrics suggest that the company is being valued primarily on its revenue generation potential rather than earnings power, a common characteristic for high-growth or loss-making biotech firms. The 52-week high is $3.18 and the 52-week low is $0.13, meaning the current trading price sits significantly below the annual high, reflecting high volatility and investor skepticism regarding near-term profitability. The stock exhibits a beta of 1.98, which signifies that the share price is highly sensitive to market movements and fluctuates nearly twice as much as the broader market index.

Growth & Income

Revenue growth year-over-year is -96.5%, while earnings growth is not applicable (N/A) due to prior period losses, indicating that the company is currently shrinking in terms of top-line performance rather than expanding. Since the company is not a dividend payer, there is no dividend yield or payout ratio to analyze for sustainability, and the company currently reinvests its limited resources into growth initiatives rather than distributing income to shareholders. The overall growth and income profile is characterized by significant contraction in revenue and a complete absence of dividend income, reflecting the high-risk, early-stage nature of the enterprise within the healthcare diagnostics sector. The financial data underscores a trajectory of negative growth metrics where the company has yet to transition from a cash-burning startup phase to a profitable commercial operation.